Nitrosamine Impurities in Pharmaceuticals: Integrated Evaluation of Toxicity, Exposure, Carcinogenic Potency Categorization and Regulatory Risk Assessment

The emergence of N-nitrosamine impurities in pharmaceutical products represents one of the most significant challenges to global drug safety and regulatory oversight in the 21st century^[1]. These compounds, characterized by the nitroso functional group bonded to a nitrogen atom are classified as potent genotoxic and mutagenic agents belonging to the "Cohort of Concern^"[2,3]. Unlike standard pharmaceutical impurities, nitrosamines are high-potency carcinogens for which even trace-level exposure over a lifetime is associated with an increased risk of cancer^[4,5].

The current global scrutiny began in mid-2018 following the discovery of N-nitrosodimethylamine in several batches of valsartan, a widely prescribed angiotensin II receptor blocker^[6,7]. This finding triggered a series of large-scale product recalls and was followed by the identification of nitrosamines in other blockbuster medications, including the H2 -receptor antagonist ranitidine, the anti-diabetic agent metformin and the smoking cessation aid varenicline^[1,8]. By early 2025, the landscape of the "nitrosamine saga" had shifted from simple small-molecule byproducts to structurally complex Nitrosamine Drug Substance-Related Impurities, which now constitute over 90% of reported cases^[9,10]. From a chemical perspective, nitrosamines typically form through the reaction of secondary or tertiary amines with nitrosating agents, such as nitrites, under acidic conditions^[11,12]. The risk of formation exists throughout the pharmaceutical lifecycle, spanning active pharmaceutical ingredient synthesis, drug product formulation, and shelf-life storage^[3,13]. The complexity of these impurities is heightened by the fact that precursors like nitrites are ubiquitous in common excipients (e.g., microcrystalline cellulose, starch) and even in the water used during manufacturing processes^[5,14]. Toxicologically, nitrosamines are pro-carcinogens that require metabolic activation, primarily through cytochrome P450-mediated α -hydroxylation, to form highly reactive electrophilic intermediates capable of alkylating DNA^[4,15]. This activation pathway leads to the formation of stable DNA adducts and subsequent point mutations, which can initiate the carcinogenic process^[15,16]. Consequently, regulatory bodies such as the US Food and Drug Administration and the European Medicines Agency have established strict Acceptable Intake limits, often in the nanogram-per-day range, based on a theoretical excess lifetime cancer risk of 1 in 100,000^[10,17]. As the industry moves forward, the focus has expanded toward integrated risk management strategies^[18,19]. This includes the development of the Carcinogenic Potency Categorization Approach to establish safe limits for NDSRIs that lack traditional animal carcinogenicity data^[17,20]. Furthermore, innovative mitigation strategies, such as the use of nitrite scavengers and high-purity excipients, are being adopted to ensure long-term product stability and patient safety^[5,21]. This review provides a comprehensive analysis of the chemical origins, toxicological mechanisms and evolving regulatory frameworks governing nitrosamine impurities aiming to offer a "source-to-solution" perspective on this critical pharmaceutical issue^[3,14].

Chemistry And Formation Of Nitrosamines

1. Chemical Structure and Mechanism of Nitrosamine Formation

N-nitrosamines are a class of organic compounds characterized by the nitroso functional group (-N=O ) directly attached to a nitrogen atom^[12]. The general chemical structure is represented as R1R2N-N=O , where R1  and R2  can be alkyl, aryl, or heterocyclic substituents^[4]. From a chemical bonding perspective, nitrosamines exhibit significant resonance stabilization between the lone pair on the amino nitrogen and the π -system of the nitroso group, resulting in a partial double-bond character for the N-N  bond^[12]. This restricted rotation contributes to the stability of the molecule and influences its unique spectroscopic and reactivity profiles^[12].

In the pharmaceutical context, these impurities are broadly classified into two categories:

1. Small-Molecule Nitrosamines:

These are low-molecular-weight compounds such as N -nitrosodimethylamine and N -nitrosodiethylamine^[10]. They are typically non-drug-related and often arise as byproducts of manufacturing through the use of contaminated solvents or specific reagents^[6,10].

2. Nitrosamine Drug Substance-Related Impurities:

These are complex N -nitroso compounds formed directly from the active pharmaceutical ingredient or its structurally related fragments^[5,9]. NDSRIs represent a more modern challenge, now accounting for over 90% of reported nitrosamine cases as of early 2025^[10].

The predominant pathway for nitrosamine formation is the N -nitrosation of amine precursors by electrophilic nitrosating agents^7,11. Secondary amines are the most reactive substrates, typically reacting with nitrous acid (HNO2 ) in aqueous acidic environments^[22,23]. The reaction kinetics are generally third-order with the rate proportional to the concentration of the free amine and the square of the nitrous acid concentration:

 Rate=kAmineHNO22 ^[23,24].

The active nitrosating species is frequently dinitrogen trioxide (N2O3 ), formed through the dehydration of two nitrous acid molecules, although other potent agents such as nitrosyl chloride (NOCl ), dinitrogen tetroxide (N2O4 ), and various nitrogen oxides (NOx ) can also drive the reaction^[11,22,23]. While primary amines typically form unstable diazonium salts that rapidly decompose, secondary amines yield stable N -nitrosamines^[7]. Tertiary amines and quaternary ammonium compounds can also yield nitrosamines through slower nitrosative dealkylation or cleavage processes, particularly under conditions of elevated temperature or prolonged exposure to nitrosating agents^[7,9,24].

2.  Sources of Nitrosamine Formation in Pharmaceuticals

Nitrosamine contamination can occur at multiple stages of the product lifecycle, from API synthesis to final drug product storage^[1,3]:

• API Synthesis: The use of sodium nitrite in processes like tetrazole ring formation, the presence of secondary amines as reagents or catalysts (e.g., triethylamine), and the use of contaminated or recovered solvents (e.g., dimethylformamide, toluene) are primary risk factors^[6,10].
• Manufacturing Environment: Trace nitrites have been identified in common reagents, including sodium azide and activated charcoal, and can even be present in purified water systems used during processing^[3,6].
• Excipients: Many solid dosage excipients, such as microcrystalline cellulose, starch, and crospovidone, contain trace levels of nitrites (typically < 2 ppm)^[5,10]. These trace amounts are sufficient to react with secondary amine APIs to form NDSRIs during formulation or storage^[5,14].
• Packaging Materials: Interaction with nitrocellulose-based printing inks in lidding foils or the migration of nitrosamines from blister pack materials can introduce these impurities into the final product^[1,25].

3. Nitrosamine Drug Substance-Related Impurities

NDSRIs are a subset of nitrosamines where the nitroso group is attached to the parent drug molecule itself^[5]. Because many APIs contain secondary or tertiary amine functional groups, they are inherently prone to nitrosation^[9,26]. Unlike small-molecule nitrosamines, which can often be purged during API purification, NDSRIs often form within the drug product matrix during manufacturing (e.g., wet granulation) or over the course of its shelf life^[5,8]. Notable examples include N -nitroso-varenicline, N -nitroso-duloxetine, and N -nitroso-fluoxetine^[9,27]. These impurities pose a significant challenge because they are structurally unique to each API, often requiring custom analytical methods and structural-activity relationship analysis to determine safe intake limits in the absence of pre-existing carcinogenicity data^[20,26].

The rate and extent of nitrosamine formation are governed by several critical physicochemical parameters^[7,12]:

• pH Profile: The reaction typically reaches its maximum rate at pH 3.0–3.4, where the concentration of both the unprotonated amine and the reactive nitrosating species is optimized^[23,24]. However, formation has been observed under both highly acidic gastric conditions and more neutral formulation environments^[5,28].
• Temperature and Time: Elevated temperatures during drying or storage significantly accelerate nitrosation kinetics^[3,7]. Furthermore, the total concentration of nitrosamines often increases cumulatively throughout the product's shelf life as the reaction proceeds within the solid dosage form^[5].
• Moisture Content: The presence of moisture or high humidity can facilitate the mobilization of nitrites and amines within a tablet matrix, enhancing their reactivity^[3,5].
• Catalysts and Inhibitors: Certain salts or metal ions can act as catalysts, while antioxidants such as ascorbic acid, alpha-tocopherol and various amino acids can act as potent inhibitors by scavenging nitrosating agents before they react with the amine precursors^[5,7,29].

A comprehensive understanding of these formation pathways and influencing factors is essential for the development of effective mitigation strategies and control of nitrosamine impurities in pharmaceutical products.

Toxicological Aspects Of Nitrosamines

1. Mechanism of Toxicity and Metabolic Activation

Nitrosamines are recognized as some of the most potent genotoxic carcinogens, exhibiting the ability to induce tumors in multiple species and across a wide range of target organs including the liver, oesophagus and respiratory tract^[1,4]. Within the regulatory framework of mutagenic impurities, they are classified as part of the "Cohort of Concern," a group of high-potency compounds for which the standard Threshold of Toxicological Concern (1.5 μg/day) is considered insufficiently protective^[2,3]. The International Agency for Research on Cancer has classified common nitrosamines like NDMA and NDEA as Group 2A carcinogens (probably carcinogenic to humans), based on robust evidence from experimental animal models and strong mechanistic data indicating shared metabolic pathways with humans^[1,10,15]. Nitrosamines are pro-carcinogens that remain chemically stable until they undergo metabolic activation within the body^[4,15]. This process is primarily mediated by cytochrome P450 enzymes, particularly the CYP2E1 and CYP2A6 isoforms, which exhibit high variability among individuals^[4,30]. The critical step in activation is α -hydroxylation, where a hydroxyl group is introduced at the carbon atom adjacent to the nitroso nitrogen^[4,31].

The resulting α -hydroxy nitrosamine is highly unstable and undergoes spontaneous decomposition to form an aldehyde and a diazohydroxide^[15,31]. This diazohydroxide subsequently generates a highly reactive alkyldiazonium ion, an electrophilic species capable of covalently binding to nucleophilic sites in DNA^[15,32]. Emerging research has also identified an alternative pathway involving the formation of nitrosamides during CYP450 metabolism, which similarly yields reactive electrophiles that contribute to the overall genotoxic burden^[31,32].

2. Genotoxicity, Carcinogenicity and Dose–Response

The carcinogenicity of nitrosamines stems from the formation of stable DNA adducts that interfere with normal replication[^4,15]. The most significant adduct is O6 -alkylguanine, particularly O6 -methylguanine derived from NDMA^[4,16]. This specific modification is highly mutagenic because it has a potential to incorrectly pair with thymine during DNA synthesis, leading to G:C  to A:T  transition mutations^[15,16]. Other common adducts include 7-methylguanine and 3-methyladenine; while less directly mutagenic, their accumulation contributes to genomic instability^[4]. Because nitrosamines are assumed to act through a non-threshold, DNA-reactive mechanism, regulatory risk models assume that any level of exposure increases the probability of a mutational event that could initiate cancer^[2,10]. The carcinogenic potency of a nitrosamine is strongly influenced by its chemical structure^[20,33].

The potency of nitrosamines varies by several orders of magnitude, traditionally characterized by the TD50  value, the daily dose required to induce tumors in 50% of test animals^[20,34]. For instance, NDEA is significantly more potent than NDMA, reflected in its lower TD50  and more stringent intake limits^[33,34]. Because of their genotoxicity, regulators employ linear extrapolation from these high-dose animal studies to calculate a dose corresponding to a 1 in 100,000 theoretical lifetime cancer risk in humans^[10,20]. This approach results in Acceptable Intake limits that range from as low as 18 ng/day for the most potent compounds to 1500 ng/day for those with deactivating structural features^[17,20].

3. Structure–Activity Relationship

A fundamental requirement for high potency is the presence of α -hydrogen atoms, which are necessary for the initial metabolic hydroxylation step^[4,12]. Steric hindrance plays a major role; bulky substituents adjacent to the nitroso group can significantly reduce potency by hindering enzymatic access to the α -carbon^[9,12]. Additionally, the presence of electron-withdrawing groups can deactivate the molecule, while the length and symmetry of alkyl chains influence both the overall potency and the specific organs targeted for tumor formation^[12,33]. These relationships form the scientific basis for the Carcinogenic Potency Categorization Approach used to predict the risk of novel impurities^[20,33].

NDSRIs pose a unique toxicological challenge because they are often proprietary molecules with no prior experimental carcinogenicity data^[5,26]. As they represent over 90% of current nitrosamine concerns, the lack of data has forced a shift toward the CPCA framework, which categorizes these impurities based on structural alerts and metabolic likelihood^[10,20]. However, uncertainties remain regarding how complex drug-like structures affect the stability of the resulting diazonium ions and the efficiency of DNA alkylation^[2,9]. Current research is focused on developing refined in vitro assays and in silico models to better predict the actual mutagenic potential of these complex impurities without relying exclusively on structural surrogates^[9,18].

Overall, the toxicological profile of nitrosamines highlights the necessity of integrating mechanistic understanding, structural characteristics, and dose–response relationships to support scientifically justified risk assessment.

Exposure Assessment And Lifetime Risk Evaluation

1. Exposure Estimation and Lifetime Risk Concept

Exposure to nitrosamine impurities in a pharmaceutical context is defined as the estimated daily intake of a specific nitrosamine from a medicinal product by a patient^[10,25]. This value is expressed in nanograms per day (ng/day) and represents the actual systemic burden of the mutagenic impurity^[10]. Unlike standard pharmaceutical impurities that are controlled as a percentage of the active substance, nitrosamine exposure is evaluated based on absolute daily mass to account for their high carcinogenic potency^[1,2].

The daily exposure is quantitatively estimated by multiplying the concentration of the nitrosamine impurity found in the drug product (often measured in parts per billion or ng/g) by the maximum daily dose prescribed for the medication[^10,25].

The formula used by industry and regulators  is:
 

Daily Exposure (ng/day)=Concentration (ng/mg)×MDD (mg/day)

Where MDD is the Maximum Daily Dose as defined in the product's approved labelling^[6,25]. This ensures that the risk assessment covers the "worst-case" exposure scenario for a patient^[10].

The toxicological risk assessment for nitrosamines is built upon a conservative "lifetime exposure" model. This model assumes that a patient consumes the medication daily at the maximum dose for a total of 70 years^[10,17]. The acceptable intake limits are derived such that this 70-year exposure corresponds to a theoretical excess cancer risk of 1 in 100,000 (10??)^[7,17]. Regulators emphasize that this numerical risk is a highly conservative, theoretical construct used to establish safety margins rather than a realistic prediction of clinical cancer incidence^[2,17].

2. Acceptable Intake and Risk Interpretation

The Acceptable Intake is the maximum daily mass of a nitrosamine that is considered to pose a negligible risk under the 70-year assumption^[10,20]. Regulatory authorities have established default AI limits for nitrosamines without compound-specific data: the EMA generally applies a limit of 18 ng/day, while the US FDA has established a default of 26.5 ng/day^[9,10].

• Acceptable: If estimated exposure is less than or equal to the AI.
• Unacceptable: If exposure exceeds the AI, requiring immediate mitigation, batch recalls, or process modifications^[5,10].

The acceptable intake limits for commonly reported nitrosamines vary depending on their carcinogenic potency, as summarized in Table 1.

Acceptable intake limits for nitrosamines derived from carcinogenic potency data corresponding to a theoretical excess lifetime cancer risk of 1 in 100,000 under a 70-year exposure scenario.

3. Less-Than-Lifetime Exposure

To illustrate, if a drug product with a Maximum Daily Dose of 1,000 mg is found to contain 0.05 ppm (50 ng/g) of NDMA, the daily exposure is calculated as 50 ng/day^[25]. If the established AI for NDMA is 96 ng/day, this product would be considered acceptable^[10]. However, if the same product contained 0.15 ppm (150 ng/g), the daily exposure would be 150 ng/day, exceeding the limit and necessitating regulatory action^[10,25]. A real-world case study on a marketed drug demonstrated that validating the analytical procedure is the first critical step before making risk mitigation decisions based on these exposure calculations^[35].

For medications intended for short-term use (e.g., antibiotics or acute pain relief), applying a 70-year exposure model may be excessively conservative^[2,10]. In these cases, regulators may permit "Less-Than-Lifetime" limits. Based on ICH M7 principles, the daily intake can be adjusted upward depending on the duration of treatment:

• < 1 month: Up to 120 µg/day (for general mutagenic impurities, though nitrosamines          remain more strictly controlled)^[2,5].
• 1–12 months: Intermediate limits are applied based on a cumulative dose approach^[2,10].

When a drug product contains more than one nitrosamine (e.g., both NDMA and NDEA), the risk assessment must account for their combined effect^[9,10]. The sum of all nitrosamines present should generally not exceed the AI of the most potent nitrosamine identified in the mixture or a total limit of 26.5 ng/day under certain FDA criteria^[7,10]. This cumulative approach prevents the additive carcinogenic burden that could arise from multiple trace impurities^[9,10].

Total patient exposure is the result of cumulative contamination from several sources throughout the product lifecycle^[3,7]:

• API Manufacturing: Residual solvents, reagents, and catalysts^[6].
• Excipients: Trace nitrites in fillers and binders (e.g., 2 ppm in microcrystalline    cellulose can yield significant NDSRIs)^[5,10].
• Processing: Use of recycled solvents or contaminated water systems^[3,36].
• Packaging: Migration of nitrosating agents from blister pack lidding foils^[1,25].

Exposure assessment is part of a multi-tiered risk evaluation framework rather than an isolated procedure^[10,20]. Manufacturers first use the Threshold of Toxicological Concern (1.5 µg/day) as a general screening tool for mutagenic impurities^[10]. If a nitrosamine is suspected, the Carcinogenic Potency Categorization Approach is used to assign a structural potency category (Categories 1–5), which dictates the specific AI limit (from 18 ng/day to 1500 ng/day) against which the estimated exposure is compared^[9,20]. Collaborative reliance among different countries' regulatory authorities has been shown to improve the efficiency of handling these complex risk assessments^[37].

Thus, accurate estimation of daily exposure and its comparison with acceptable intake limits derived from lifetime risk assumptions form the quantitative basis for subsequent risk assessment approaches.

Risk Assessment Approaches: Ttc, Cpca, And Acceptable Intake Integration

1. Evolution of Risk Framework and TTC Limitations

The regulatory approach to nitrosamine risk assessment has undergone a significant paradigm shift from a conservative, one-size-fits-all default to a scientifically rigorous, structure-based categorization model^[10,20]. This transition was driven by the global discovery of thousands of potential Nitrosamine Drug Substance-Related Impurities for which traditional, long-term animal carcinogenicity data were non-existent^[9,10,20]. Today, a tiered framework is utilized, integrating the Threshold of Toxicological Concern for preliminary screening, the Carcinogenic Potency Categorization Approach for structural assessment and compound-specific Acceptable Intake limits for definitive safety characterization^[10,17,19].

The TTC is a fundamental principle established in the ICH M7(R2) guideline, setting a generic safety limit of 1.5 μg/day (1500 ng/day) for most mutagenic impurities^[10,38]. This value corresponds to a theoretical lifetime cancer risk of 1 in 100,000 and is intended to provide a high level of protection for compounds without specific toxicological data^[38,39].

However, nitrosamines are explicitly excluded from the standard 1500 ng/day TTC because they are classified as part of the "Cohort of Concern" compounds with such high carcinogenic potency that even doses below 1.5 μg/day may pose significant risks^[2,39,40]. For this cohort, regulators historically applied a class-specific default limit of 18 ng/day^[9,17]. While this 18 ng/day limit ensured patient safety, it often resulted in unnecessary drug recalls for structurally complex nitrosamines that were later found to have lower potency^[17,20].

2. CPCA and Acceptable Intake Derivation

Introduced in 2023, the CPCA is a refined, structure-activity relationship methodology that assigns nitrosamines to one of five potency categories based solely on their structural features^17,20,41. This approach allows for a more resolved assessment of risk by identifying structural alerts that either activate or deactivate the nitrosamine's mutagenic potential^[20,33].

The categorization is based on a point-based scoring system that evaluates:

• α -Hydrogen Count: The presence of hydrogen atoms on the carbon adjacent to the nitroso group is essential for metabolic activation; fewer hydrogens often correlate with lower potency^[4,17,20].
• Deactivating Structural Features: Functional groups such as carboxylic acids (-COOH), sulfonic acids (-SO3H), and large, bulky substituents provide electronic deactivation or steric hindrance, reducing the rate of α -hydroxylation^[20,42,43].
• Ring Size and Heteroatoms: In cyclic nitrosamines, the presence of specific ring structures can significantly influence the stability of the resulting reactive intermediates^[20,43].

Nitrosamines are categorized into different potency classes based on structural features influencing carcinogenicity, as outlined in Table 2.

CPCA categorizes nitrosamines based on structural features influencing carcinogenic potency, enabling compound-specific acceptable intake determination.  To ensure the reliability of these predictions, modern risk assessments now incorporate "Confidence Score" calculations to quantify the probability that a structural assignment is accurate⁴¹. The AI represents the maximum daily mass of a nitrosamine considered to result in a negligible risk of cancer (10??) over a 70-year lifetime^[10,34,39]. For well-characterized nitrosamines, the AI is derived using linear extrapolation from animal carcinogenicity data, specifically the TD50  (toxic dose for 50% of the population)^[20,34,44].

The standard calculation is:
AI=TD5050,000×50kg

This formula assumes a 50 kg body weight and a lifetime of daily exposure^[10,20]. More recently, the use of the Benchmark Dose methodology, specifically the lower bound of the 10% benchmark dose (BMDL10 ), has been championed as a more robust statistical alternative to the TD50  method for deriving AI limits from modern cancer bioassays^[44–46].

Risk Assessment And Decision Strategy

A systematic workflow is now expected for quality risk management of nitrosamines^[17,19]. This involves a four-step process:

1. Risk Identification: Assessing the API synthetic route and excipient profile for potential precursors^[5,6].
2. Confirmatory Testing: Quantifying suspected impurities at trace levels using validated LC-MS/MS or GC-MS/MS^[10,47,48].
3. Category Assignment: Applying CPCA structural scoring to determine the appropriate AI^[20,41].
4. Refined Toxicological Testing: If the impurity exceeds the CPCA-assigned AI, manufacturers may perform an Enhanced Ames Test^[49,50]. Recent research highlights that optimizing the Ames test with hamster-induced liver S9 and specific pre-incubation steps is critical for accurately predicting the carcinogenic potential of N-nitrosamines^[49–51].

A comparative overview of TTC, CPCA, and acceptable intake approaches is presented in Table 3, highlighting their respective roles in nitrosamine risk assessment.

When substance-specific data are absent as is the case for most NDSRIs, regulators permit a "read-across" approach^[9,26,52]. This strategy identifies a structurally similar nitrosamine (a "surrogate") with robust carcinogenicity data to justify a safe intake limit for the target impurity^[9,52]. To provide additional scientific support, quantum chemical evaluation and QSAR modeling are used to calculate reaction barriers for metabolic activation, proving that the target NDSRI is no more potent than its chosen surrogate^[42,53,54]. The adoption of the CPCA by the FDA, EMA, and Health Canada in 2023 represents a milestone in global regulatory harmonization^[10,41,55]. Future trends in risk assessment include the transition toward "Less-Than-Lifetime" limits for medications with short treatment durations, such as acute antibiotics or diagnostic agents, where the 70-year exposure assumption is biologically irrelevant^[2,5,10]. Additionally, there is a push for more "mechanistically informed" risk management that moves beyond structural alerts to include high-fidelity in vitro data and kinetic modeling of nitrosation rates in drug matrices^[9,18,56].

The integration of TTC, CPCA, and acceptable intake approaches represents a progressive shift toward more refined and compound-specific risk assessment of nitrosamine impurities.

Regulatory Perspectives And Global Guidelines

1. Global Regulatory Framework and Evolution

The global response to nitrosamine contamination has evolved into a comprehensive, risk-based regulatory framework driven by international collaboration and scientific advancement. The discovery of N-nitrosodimethylamine in valsartan in June 2018 triggered an unprecedented global regulatory response that fundamentally reshaped pharmaceutical impurity management^[6,39]. This crisis necessitated a shift from reactive market recalls to a comprehensive, proactive regulatory framework characterized by intense international cooperation^[10,39]. Health authorities worldwide recognized that nitrosamines posed a unique systemic threat because they could form from common manufacturing practices and were present as trace contaminants in widely used medications^[1,6]. The scale of the response was remarkable: by early 2020, the European Medicines Agency had launched an Article 31 referral procedure, which eventually expanded to cover all chemically synthesized drug products^[1,39]. Simultaneously, the US Food and Drug Administration issued multiple alerts affecting dozens of medications, including ranitidine, metformin, and various angiotensin receptor blockers^6,10. This coordinated action represented a paradigm shift toward a systematic, risk-based approach applicable to entire pharmaceutical portfolios^[6,10]. The regulatory landscape continues to evolve toward a more science-led paradigm^[10,20]. The adoption of the CPCA represents a shift toward more sophisticated, structure-based risk assessment^[17,20]. Regulators are increasingly accepting "Less-Than-Lifetime" approaches and the use of structural surrogates for AI derivation when substance-specific data are missing^[10,52].

2. Regulatory Approaches: FDA, EMA, and Global Agencies

The FDA's regulatory framework for nitrosamines is anchored in its final guidance, "Control of Nitrosamine Impurities in Human Drugs," originally issued in September 2020 and updated to reflect evolving science^[6,10]. This guidance establishes clear expectations for manufacturers and distributors across the drug supply chain. The FDA adopted a tiered risk management approach:

1. Risk Evaluation: Manufacturers must identify potential sources of nitrosamine formation in all marketed products and APIs^[6].
2. Confirmatory Testing: For products identified as at-risk, manufacturers must perform high-sensitivity testing using validated methods^[5,6].
3. Reporting and Remediation: Implementation of control strategies and submission of changes to ensure ongoing compliance^[6,10].

The FDA established specific AI limits based on lifetime cancer risk, such as 96 ng/day for NDMA, and has been a leading advocate for the implementation of the Carcinogenic Potency Categorization Approach for complex NDSRIs^[10,20]. The EMA's response was spearheaded through its Committee for Medicinal Products for Human Use, which managed the Article 5 referral procedure^[10,39]. The EMA issued a comprehensive "Questions and Answers" document (EMA/409815/2020) that serves as the primary reference for EU member states, providing updated AI limits and refined risk assessment methodologies^[20,39]. The EMA established strict compliance timelines, requiring chemical medicines to complete risk evaluations by March 2021 and confirmatory testing/controls by September 2023^[10]. For biological medicines, these deadlines were extended to July 2021 and July 2025, respectively^[10]. The EMA was instrumental in developing the CPCA framework and was among the first regulators to adopt it in mid-2023, providing a rapid categorization system for NDSRIs based on structural features that influence metabolic activation^[17,20]. Health Canada has maintained close alignment with both the FDA and EMA, issuing its own guidance that mirrors the three-step risk management process^[10,55]. Other major agencies, such as the Swiss Agency for Therapeutic Products and the Australian Therapeutic Goods Administration, have also adopted similar frameworks^[6,41]. This convergence is critical for global manufacturers, as it allows for a unified approach to risk assessments and control strategies across different markets^[17,20]. The WHO plays a vital role in global harmonization, particularly for international markets and low- and middle-income countries^[1,3]. The WHO has issued multiple guidance documents emphasizing the need for systematic risk assessment across all national regulatory authorities^[1,10]. Its contribution is valuable in ensuring that regulatory efforts in major markets do not inadvertently create drug shortages in vulnerable regions^[1,3]. By disseminating information on detection methods and risk assessment procedures, the WHO helps build capacity in national regulatory agencies worldwide^[1,10].

3. Harmonization, Industry Responsibilities, and Future Trends

The Nitrosamines International Strategic Group has been a driving force behind global harmonization^[6,10]. This group includes representatives from the FDA, EMA, Health Canada, and Swissmedic^[6,41]. Their primary mandate is to share scientific knowledge, discuss complex cases, and develop unified approaches to common challenges like AI derivation and CPCA implementation^[17,20]. While the ICH M7(R2) guideline provides the foundation for mutagenic impurity assessment, the NISG develops nitrosamine-specific supplemental guidance to prevent regulatory divergence^[6,10]. Recent studies have highlighted the value of "collaborative reliance" among regulators to improve the efficiency of handling these complex impurities^[37]. Regulatory authorities have placed the responsibility for patient safety squarely on the pharmaceutical industry^[6,10]. Manufacturers are required to conduct comprehensive risk assessments for all marketed products and APIs, examining all potential sources including synthetic routes, reagents, solvents, excipients, and packaging materials^[1,3]. When risks are identified, manufacturers must implement robust control strategies, such as process modifications, alternative reagent sourcing, or the use of nitrite scavengers in formulations^[5,7]. A case study on a marketed drug demonstrated that validating the analytical procedure is the critical first step before a risk mitigation decision can be made^[35].

There is also a growing recognition of the need for integrated quality risk management workflows that cover both the drug substance and the drug product throughout its lifecycle^[17,19]. Finally, there is a push for enhanced international collaboration on post-market surveillance to identify systemic risks across the global supply chain^[1,6].

These evolving regulatory frameworks collectively emphasize a harmonized, risk-based approach to ensure the safety and quality of pharmaceutical products worldwide.

Challenges And Future Perspectives

1. Analytical and Toxicological Challenges

The determination of nitrosamine impurities remains one of the most demanding analytical tasks in pharmaceutical quality control due to the requirement for ultra-sensitive methods capable of detecting trace levels in complex drug matrices^[47,57]. Achieving sensitivity in the parts-per-billion (ppb) or parts-per-trillion (ppt) range typically necessitates advanced hyphenated techniques such as LC-MS/MS or GC-MS/MS^[47,58]. These methods must be meticulously validated to ensure accuracy and precision at levels far below standard impurity thresholds^[47,59]. A significant hurdle is the risk of artifactual nitrosamine formation during sample preparation or analysis, where residual amines and nitrosating agents in the laboratory environment can react, leading to false-positive results^[1,47]. Furthermore, the presence of isobaric interferences and matrix effects can complicate the identification of low-level impurities^[47,60]. To address these challenges, researchers are exploring innovative approaches such as QSRR modeling for ultra-sensitive trace analysis and the development of optimized LC-MS methods for better separation of complex nitrosamine mixtures^[27,60,61]. Recent studies have also highlighted the importance of assessing nitrosamine risks not just in the API, but also in secondary packaging and pharmaceutical packaging materials, which can be an overlooked source of contamination^[1,25]. Nitrosamine Drug Substance-Related Impurities represent a unique scientific hurdle because they lack the extensive historical carcinogenicity data available for simple small-molecule nitrosamines^[5,8]. Currently, NDSRIs account for over 90% of identified nitrosamine concerns, yet many have no known TD50  values, forcing regulatory reliance on structure-activity relationship modeling and read-across methods^[9,10,20]. Standard genotoxicity tools like the Ames test are often considered insufficiently sensitive for de-risking these complex molecules without modification^[8,16]. Advanced toxicological research is now focusing on the formation of DNA methylation adducts in primary hepatocytes upon cytochrome P450-dependent metabolic activation, providing more biologically relevant evidence of mutagenic potential^[28,62]. Furthermore, the development of the Carcinogenic Potency Categorization Approach and the calculation of associated confidence scores are critical for refining acceptable intake limits for novel impurities^[20,41]. There is an urgent need for more robust in vitro and in vivo data to bridge the current gaps and move away from overly conservative default limits^[2,9,18].

2. Mitigation Strategies and Formulation Innovations

The shift toward a "Quality by Design" approach is essential for long-term nitrosamine risk management^[3,19]. A primary mitigation strategy involves the systematic selection of excipients with low nitrite content, as even trace nitrites (below 2 ppm) in common fillers like microcrystalline cellulose can drive nitrosation reactions within the solid dosage form ^5,8,63. Manufacturers are increasingly using liquid chromatography-tandem mass spectrometry to quantitate nitrite in excipients at trace levels to ensure raw material quality^[5,64]. Formulation innovations, such as the incorporation of nitrite scavengers (e.g., ascorbic acid, alpha-tocopherol, or amino acids), have proven effective in inhibiting the formation of both alkyl-aryl and dialkyl N-nitrosamine derivatives^[7,29,65]. Modeling the impact of excipient selection on nitrosamine formation allows for the development of "source-to-solution" management plans that stabilize the drug product throughout its shelf life^[14,21,63]. Additionally, improving manufacturing processes to avoid high-risk reagents and implementing more rigorous control of recovered solvents are fundamental to reducing the initial impurity burden^[3,6].

3. Regulatory and Future Directions Perspectives

The complexity of the global response to nitrosamines has underscored the need for unprecedented collaborative reliance among regulatory authorities^[6,37]. Efforts by the Nitrosamines International Strategic Group are focused on aligning acceptable intake limits and risk assessment methodologies across major jurisdictions to prevent regulatory divergence^[6,10,17]. This harmonization is critical for maintaining the stability of the international drug supply and preventing localized shortages^[10,37]. Collaborative research initiatives are also essential for advancing the field^[5,47]. Sharing toxicological data, analytical methodologies, and experiences with root cause investigations allows for faster identification of systemic risks^[6,57]. As scientific understanding matures, these collaborative efforts are expected to lead to more refined, data-driven guidelines that better reflect the clinical reality of patient exposure while ensuring the highest standards of safety^[5,10,41]. The future of nitrosamine regulation is moving toward a more nuanced, science-led paradigm that prioritizes structural risk over generic thresholds^[10,20]. The adoption of the CPCA framework signals a move away from the conservative 18 ng/day default toward structure-based de-risking^[9,17,20]. We can anticipate further refinements in the derivation of compound-specific Acceptable Intakes as more structural-activity relationship data becomes available^[9,17].

Regulators are also increasingly emphasizing integrated quality risk management workflows that bridge the gap between drug substance and drug product manufacturing^[5,19]. This includes the implementation of life-cycle management strategies that account for potential nitrosamine formation during storage and the impact of packaging on product stability^[10,19]. Finally, as more data on long-term clinical outcomes are collected, the current conservative 70-year lifetime exposure model may be refined to provide a more accurate assessment of patient risk in diverse therapeutic settings^[5,10].

CONCLUSION

Nitrosamine impurities represent a unique and complex challenge in pharmaceutical development and quality assurance due to their high carcinogenic potency, diverse formation pathways, and occurrence at trace levels across multiple stages of the product lifecycle. Unlike conventional impurities, their risk cannot be adequately managed using generic thresholds, necessitating a paradigm shift toward scientifically robust, exposure-driven risk assessment frameworks. The integration of daily exposure estimation (ng/day), lifetime risk assumptions, and compound-specific acceptable intake limits forms the cornerstone of modern nitrosamine risk evaluation. The emergence of the carcinogenic potency categorization approach has significantly advanced the field by enabling structure-based classification and refined acceptable intake derivation, particularly for nitrosamine drug substance-related impurities where experimental data are limited. Despite substantial progress, critical challenges remain, including analytical complexities at ultra-trace levels, uncertainties in toxicological data for novel nitrosamines, and the need for harmonized global regulatory approaches. Addressing these challenges will require continued advancements in analytical methodologies, computational toxicology, and collaborative regulatory efforts. Future risk management strategies should emphasize a life-cycle approach integrating process design, formulation control, and post-market surveillance to minimize nitrosamine formation. As scientific understanding evolves, there is a growing opportunity to move toward more mechanistically informed and less conservative risk assessment models that better reflect real-world exposure while maintaining the highest standards of patient safety.

REFERENCES

1. Vikram HPR, Kumar TP, Kumar G, Beeraka NM, Deka R, Suhail SM, et al.: Nitrosamines crisis in pharmaceuticals: Insights on toxicological implications, root causes and risk assessment: A systematic review. Journal of Pharmaceutical Analysis 2024; 14(5): 100919.
2. Snodin DJ: Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines. Regulatory Toxicology and Pharmacology 2023; 141: 105355.
3. Sharma V, Singh R: A review on mechanism of nitrosamine formation, metabolism and toxicity in in vivo. International Journal of Toxicological and Pharmacological Research 2014; 6(4): 86–96.
4. Nudelman R, Kocks G, Mouton B, Ponting DJ, Schlingemann J, Simon S, et al.: The nitrosamine “saga”: Lessons learned from five years of scrutiny. Organic Process Research & Development 2023; 27.
5. Li Y, Hecht SS: Metabolic activation and DNA interactions of carcinogenic N-nitrosamines to which humans are commonly exposed. International Journal of Molecular Sciences 2022; 23(9): 4559.
6. Snodin DJ, Trejo-Martin A, Ponting DJ, Smith G, Czich A, Cross KP, et al.: Mechanisms of nitrosamine mutagenicity and their relationship to rodent carcinogenic potency. Chemical Research in Toxicology 2024; 37(2): 181–196.
7. Wichitnithad W, Nantaphol S, Noppakhunsomboon K, Rojsitthisak P: An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals. Saudi Pharmaceutical Journal 2023; 31(2): 295.
8. Dirat O, Urquhart MW, Akehurst H, Burns MJ, Dobo KL, Harvey J, et al.: Drug substance and drug product workflows for quality risk management for the presence of nitrosamines in medicines. Organic Process Research & Development 2025.
9. Kruhlak NL, Schmidt M, Froetschl R, Gräber S, Haas B, Horne I, et al.: Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the carcinogenic potency categorization approach (CPCA). Regulatory Toxicology and Pharmacology 2024; 150: 105640.
10. Rahangdale GD, Gupta KR, Umekar M: A review on nitrosamine management in pharmaceuticals: From source to solution. Current Analytical Chemistry 2025; 21.
11. Ponting DJ, Czich A, Felter SP, Glowienke S, Harvey J, Nudelman R, et al.: Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakes. Regulatory Toxicology and Pharmacology 2024: 105762.
12. Dande A, Mouli HMC, Nandy J, Shreya S, Pallaprolu N, Samanthula G, et al.: Risk assessment, detection and control of mutagenic impurities in pharmaceuticals: Emphasis on nitrosamines. Critical Reviews in Analytical Chemistry 2025.
13. Sayyed Mubarak Ali R, Birari DR, Patil LN: A review on nitrosamine impurities, factor affecting formation of nitrosamine impurities and systematic approach to mitigate risk in active pharmaceutical ingredients. InSight Bulletin 2025; 2(10).
14. Ukhade SS, Sonawane S: Nitrosamine contamination in pharmaceuticals: A comprehensive review on nitrosation pathways, potential root cause, detection, risk assessment and mitigation strategies. Biosciences Biotechnology Research Asia 2024; 21(3): 893–905.
15. Kawamura MY, Ponting DJ, Barber CG, et al.: Computational mechanistic study on N-nitrosation reaction of secondary amines. Journal of Molecular Modeling 2025; 31: 303.
16. Sebranek JG, Cassens RG: Nitrosamines: A review. Journal of Milk and Food Technology 1973; 36(2): 76–91.
17. Gray J, Irvine DM, Kakuda Y: Nitrates and N-nitrosamines in cheese. Journal of Food Protection 1979; 42(3): 263–271.
18. Kartop RA, Güleli M, Faruzlu FA, Çal??kan C: Evaluation of a novel LC-MS/MS based analytical method for the risk assessment of nitrosamines in pharmaceutical products and packaging materials. Journal of Pharmaceutical Sciences 2024; 113(6): 1597–1606.
19. Ashworth IW, Blanazs A, Byrne JJ, Dirat O, Fennell JW, Kuhl N, et al.: Approaches and considerations for the investigation and synthesis of N-nitrosamine drug substance-related impurities (NDSRIs). Organic Process Research & Development 2023; 27(10): 1784–1791.
20. Zhang Y, Houari S, Laethem TV, Dispas A, Ziemons E, Hubert P, et al.: Innovative QSRR modeling approach for the development of an ultra-sensitive LC-MS/MS method for trace analysis of N-nitrosamines. Journal of Pharmaceutical and Biomedical Analysis Open 2025; 6: 100064.
21. Vogel M, Escher SE, Weiler EW, Londenberg A, Deppenmeier U, Whomsley R: Quantitative investigation of nitrosamine drug substance-related impurities (NDSRIs) under artificial gastric conditions by liquid chromatography–tandem mass spectrometry and structure–activity relationship analysis. Drug Testing and Analysis 2025; 17(9): 1772–1783.
22. Bayne ACV, Misic Z, Stemmler RT, Wittner MO, Frerichs M, Bird JK, et al.: N-nitrosamine mitigation with nitrite scavengers in oral pharmaceutical drug products. Journal of Pharmaceutical Sciences 2023; 112(7): 1794–1803.
23. Camus A, Geneste O, Honkakoski P, Béréziat J, Henderson CJ, Wolf CR, et al.: High variability of nitrosamine metabolism among individuals: Role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Molecular Carcinogenesis 1993; 7(4): 268–275.
24. Carlson ES, Upadhyaya P, Hecht SS: A general method for detecting nitrosamide formation in the in vitro metabolism of nitrosamines by cytochrome P450s. Journal of Visualized Experiments 2017; (127): 56312.
25. Carlson ES, Upadhyaya P, Hecht SS: Evaluation of nitrosamide formation in the cytochrome P450-mediated metabolism of tobacco-specific nitrosamines. Chemical Research in Toxicology 2016; 29(12): 2194–2201.
26. Cross KP, Ponting DJ: Developing structure-activity relationships for N-nitrosamine activity. Computational Toxicology 2021; 20: 100186.
27. Bercu JP, Masuda-Herrera M, Trejo-Martin A, Sura P, Jolly RA, Kenyon M, et al.: Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs). Regulatory Toxicology and Pharmacology 2023; 142: 105415.
28. Zhang Y, Houari S, Van Laethem T, Kumari P, Ziemons E, Hubert P, et al.: A case study on N-nitrosamine investigation in a marketed drug: From analytical procedure validation to risk mitigation decision. Frontiers in Analytical Science 2026; 6: 1772719.
29. Borths CJ, Burr T, Figuccia A, Ford JG, Guan B, Jones MT, et al.: Nitrosamine risk assessments in oligonucleotides. Organic Process Research & Development 2023; 27(10): 1693–1702.
30. Shabangu PP, Kuwana RJ, Dube A: Collaborative reliance in medicine safety and quality regulation: Investigation of experiences in handling N-nitrosamine impurities among ZaZiBoNa participating countries. Frontiers in Medicine 2022; 9: 975032.
31. Snodin D: The cancer threshold of toxicological concern (TTC) in relation to foodstuffs and pharmaceuticals: A potentially useful concept compromised by a dubious derivation. Human & Experimental Toxicology 2018; 37(8): 789–795.
32. Ruepp R, Frötschl R, Bream R, Filancia M, Girard T, Spinei A, et al.: The EU response to the presence of nitrosamine impurities in medicines. Frontiers in Medicine 2021; 8: 782536.
33. G A: Nitrosamines: Emerging chemical contaminants of concern in pharmaceutical and biological systems. International Journal of Zoology and Applied Biosciences 2025; 10(6): 364–369.
34. Chakravarti S, Saiakhov RD, Girireddy M: Confidence score calculation for the carcinogenic potency categorization approach (CPCA) predictions for N-nitrosamines. Computational Toxicology 2024; 29: 100298.
35. Schieferdecker S, Vock E: Quantum chemical evaluation and QSAR modeling of N-nitrosamine carcinogenicity. Chemical Research in Toxicology 2025; 38(2): 325–338.
36. Thomas R, Tennant RE, Oliveira AAF, Ponting DJ: What makes a potent nitrosamine? Statistical validation of expert-derived structure–activity relationships. Chemical Research in Toxicology 2022; 35(11): 1997–2007.
37. Thomas R, Ponting DJ, Thresher A, Schlingemann J, Wills JW, Johnson GE: Critical comparison of BMD and TD50 methods for the calculation of acceptable intakes for N-nitroso compounds. Archives of Toxicology 2025; 99(3): 983–996.
38. Fitzgerald DJ, Robinson NI: Development of a tolerable daily intake for N-nitrosodimethylamine using a modified benchmark dose methodology. Journal of Toxicology and Environmental Health 2007; 70(19): 1670–1678.
39. Herrmann SS: N-nitrosamines in processed meat products – analysis, occurrence, formation, mitigation and exposure. Research Portal Denmark 2014; 172.
40. Wichitnithad W, Nantaphol S, Noppakhunsomboon K, Thitikornpong W, Rojsitthisak P: Current status and prospects of development of analytical methods for determining nitrosamine and N-nitroso impurities in pharmaceuticals. Talanta 2023; 254: 124102.
41. Upadhyay K, Mehetre J, Kumar V, Mehta T, Chowdhury AR, Ahir K: Various analytical techniques used for nitrosamine impurities in pharmaceutical dosage forms: A comprehensive review. Asian Journal of Pharmaceutical Analysis 2025; 15(1): 31–40.
42. Thomas DN, Wills JW, Tracey H, Baldwin SJ, Burman M, Williams AN, et al.: Ames test study designs for nitrosamine mutagenicity testing: qualitative and quantitative analysis of key assay parameters. Mutagenesis 2024; 39(2): 78–90.
43. Atrakchi A, Puglisi R, Bercu JP, Cheung J, Czich A, Froetschl R, et al.: Nitrosamine Ames data review and method development: Proceedings of a US FDA/HESI workshop. Mutagenesis 2026; 1–12.
44. Trejo-Martin A, Bercu JP, Thresher A, Tennant RE, Thomas R, Cross KP, et al.: Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines. Regulatory Toxicology and Pharmacology 2022; 135: 105247.
45. Ponting DJ, Dobo KL, Kenyon M, Kalgutkar AS: Strategies for assessing acceptable intakes for novel N-nitrosamines derived from active pharmaceutical ingredients. Journal of Medicinal Chemistry 2022; 65(23): 15584–15602.
46. Kostal J, Voutchkova-Kostal A: Quantum-mechanical approach to predicting the carcinogenic potency of N-nitroso impurities in pharmaceuticals. Chemical Research in Toxicology 2023; 36(2): 291–304.
47. Göller AH, Johanssen S, Zalewski A, Ziegler V: Quantum chemical calculations of nitrosamine activation and deactivation pathways for carcinogenicity risk assessment. Frontiers in Pharmacology 2024; 15: 1415266.
48. Pardeshi N, Satapara V, Patel K: Nitrosamine contamination in pharmaceuticals: Regulatory perspectives and control strategies of USFDA, EMA and HC. International Journal of Drug Regulatory Affairs 2024; 12(1): 1–10.
49. Diab S, Dominey AP, Ferrini P, Hayler J, Hermitage SA, Urquhart MW, et al.: Formation of N-nitrosamines by reaction of secondary dialkylamines with trace levels of nitrite in aqueous solution: An automated experimental and kinetic modeling study using di-n-butylamine. Organic Process Research & Development 2024; 28(1): 293–304.
50. Manchuri KM, Shaik MA, Reddy GV, Sultana N, Gogineni S: Analytical methodologies to detect N-nitrosamine impurities in active pharmaceutical ingredients, drug products and other matrices. Chemical Research in Toxicology 2024; 37(9): 1456–1470.
51. Satti P, Vallamkonda B, Sharma S, Vashistha VK: Quantitative analysis of nitrosamine impurities using liquid chromatography tandem mass spectrometry. Pure and Applied Chemistry 2026; 98(3): 443–455.
52. James MR, Edge T: Low-level determination of mutagenic nitrosamine impurities in drug substances by LC–MS/MS. LCGC Europe 2021; 34(7): 267–272.
53. Balint A, Farczádi L, Cârje A, Ion V: Development and optimization of an LC-MS method for the separation of nitrosamine impurities. Acta Marisiensis Seria Medica 2025; 71(4): 315–322.
54. Rajana N, Kulkarni GG, Balaji SKK: Review on LC-MS/MS methodologies for analysis of N-nitrosamine drug-substance-related impurities. Critical Reviews in Analytical Chemistry 2025: 1–32.
55. Vogel M, Carlsson MJ, Skowron C, Felske C, Whomsley R, Fahrer J: Nitrosamine drug substance-related impurities cause DNA methylation adducts in vitro and in primary hepatocytes upon cytochrome P450-dependent metabolic activation. Regulatory Toxicology and Pharmacology 2026; 167: 106036.
56. Berardi A, Jaspers M, Dickhoff BHJ: Modeling the impact of excipients selection on nitrosamine formation towards risk mitigation. Pharmaceutics 2023; 15(8): 2015.
57. Ahn I, Lee S, Jung M, Jeong Y, Kim JY, Kim M, et al.: Development and application of analytical methods to quantitate nitrite in excipients and secondary amines in metformin API at trace levels using liquid chromatography–tandem mass spectrometry. Chemosensors 2025; 13(8): 307.
58. Homsak M, Trampuz M, Naversnik K, Kitanovski Z, Znidaric M, Kiefer M, et al.: Assessment of a diverse array of nitrite scavengers in solution and solid state: A study of inhibitory effect on the formation of alkyl-aryl and dialkyl N-nitrosamine derivatives. Processes 2022; 10(11): 2428.
59. James MR, Edge T: Low-level determination of mutagenic nitrosamine impurities in drug substances by LC–MS/MS. LCGC Europe 2021; 34(7): 267–272.
60. Balint A, Farczádi L, Cârje A, Ion V: Development and optimization of an LC-MS method for the separation of nitrosamine impurities. Acta Marisiensis Seria Medica 2025; 71(4): 315–322.
61. Rajana N, Kulkarni GG, Balaji SKK: Review on LC-MS/MS methodologies for analysis of N-nitrosamine drug-substance-related impurities. Critical Reviews in Analytical Chemistry 2025: 1–32.
62. Vogel M, Carlsson MJ, Skowron C, Felske C, Whomsley R, Fahrer J: Nitrosamine drug substance-related impurities cause DNA methylation adducts in vitro and in primary hepatocytes upon cytochrome P450-dependent metabolic activation. Regulatory Toxicology and Pharmacology 2026; 167: 106036.
63. Berardi A, Jaspers M, Dickhoff BHJ: Modeling the impact of excipients selection on nitrosamine formation towards risk mitigation. Pharmaceutics 2023; 15(8): 2015.
64. Ahn I, Lee S, Jung M, Jeong Y, Kim JY, Kim M, et al.: Development and application of analytical methods to quantitate nitrite in excipients and secondary amines in metformin API at trace levels using liquid chromatography–tandem mass spectrometry. Chemosensors 2025; 13(8): 307.
65. Homsak M, Trampuz M, Naversnik K, Kitanovski Z, Znidaric M, Kiefer M, et al.: Assessment of a diverse array of nitrite scavengers in solution and solid state: A study of inhibitory effect on the formation of alkyl-aryl and dialkyl N-nitrosamine derivatives. Processes 2022; 10(11): 2428.